OncoMatch/Clinical Trials/NCT06912074
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Is NCT06912074 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Induction chemoimmunotherapy and Concurrent Chemotherapy for esophageal squamous cell carcinoma (escc).
Treatment: Induction chemoimmunotherapy · Concurrent Chemotherapy — This is a prospective, open-label, randomized phase II clinical trial designed to compare the efficacy and toxicity of hypofractionated concurrent chemoradiotherapy versus conventional fractionated concurrent chemoradiotherapy following induction chemoimmunotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage II, III, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No prior chemotherapy
Cannot have received: radiotherapy
No prior radiotherapy
Cannot have received: surgery
No prior surgery
Cannot have received: targeted therapy
No prior targeted therapy
Cannot have received: immunotherapy
No prior immunotherapy
Cannot have received: anti-PD-1 therapy
Prior use of any anti-PD-1 or anti-PD-L1 antibody
Lab requirements
Blood counts
FEV1 ≥1000 mL; Absolute neutrophil count ≥1.5 × 10^9/L; Platelets ≥100 × 10^9/L; Hemoglobin ≥90 g/L
Kidney function
eGFR ≥50 mL/min based on Cockcroft-Gault formula
Liver function
Serum bilirubin ≤1.5 × ULN; ALT and AST ≤2.5 × ULN
FEV1 ≥1000 mL; Absolute neutrophil count ≥1.5 × 10^9/L; Platelets ≥100 × 10^9/L; Hemoglobin ≥90 g/L; eGFR ≥50 mL/min; Serum bilirubin ≤1.5 × ULN; ALT and AST ≤2.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify